Article info
PDFRisks
Paper
First-in-human HIV-remission studies: reducing and justifying risk
- Correspondence to Professor Rebecca Dresser, Washington University Law School, One Brookings Drive, Box 1120, St. Louis, MO 63130, USA; dresser{at}wulaw.wustl.edu
Citation
First-in-human HIV-remission studies: reducing and justifying risk
Publication history
- Received September 17, 2015
- Revised March 16, 2016
- Accepted April 12, 2016
- First published May 3, 2016.
Online issue publication
January 25, 2017
Article Versions
- Previous version (3 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Phase I oncology trials: why the therapeutic misconception will not go away
- Assessing risk/benefit for trials using preclinical evidence: a proposal
- Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
- Subjects’ views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study
- The Applicability of Lean and Six Sigma Techniques to Clinical and Translational Research
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- Long term effects of locomotor training in spinal humans
- Is animal research sufficiently evidence based to be a cornerstone of biomedical research?
- The rights and wrongs of intentional exposure research: contextualising the Guatemala STD inoculation study
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)